Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,663 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07227311 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) | recruiting | Phase 2 | 200 | GlaxoSmithKlineINDUSTRY | 8 | Aug 25, 2026 | clinicaltrials |
| NCT06087653 | Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 24 | Starton Therapeutics, IncINDUSTRY | 1 | Aug 24, 2026 |
| NCT05294731 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | recruiting | Phase 1 / Phase 2 | 146 | BeiGeneINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04792502 | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | recruiting | Phase 2 | 52 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06066359 | Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma | recruiting | Phase 1 / Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 37 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 226 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT06569147 | Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07485647 | Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing | recruiting | Phase 2 | 50 | Eden BiltiboOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06376526 | IMMUNOPLANT for Newly Diagnosed Multiple Myeloma(IMMUNOPLANT) | recruiting | Phase 2 | 150 | Dickran Kazandjian, MDOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06627751 | Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05850234 | AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)(DURGA-1) | recruiting | Phase 1 / Phase 2 | 232 | AstraZenecaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07673367 | Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05091372 | Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | recruiting | Phase 2 | 94 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06762431 | Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.(VTB-CLL002) | recruiting | Phase 1 / Phase 2 | 24 | Vitebsk Regional Clinical Cancer CentreOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07463807 | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment | recruiting | Phase 1 / Phase 2 | 162 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06792825 | HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL | recruiting | Phase 2 | 65 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06849713 | Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL | recruiting | Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07191249 | Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .(SUNFLOW) | recruiting | Phase 2 | 40 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03136146 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05389293 | A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma | recruiting | Phase 2 | 152 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06105554 | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06207799 | Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05632380 | ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06486051 | A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma(ENABLE-2) | recruiting | Phase 2 | 60 | Malaghan Institute of Medical ResearchOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07409454 | MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma(CAREMM-007) | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06483100 | Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance | recruiting | Phase 2 | 65 | Washington University School of MedicineOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | recruiting | Phase 1 / Phase 2 | 32 | Vironexis Biotherapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07024706 | Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab(MAVRiC) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 8 | Aug 6, 2026 | clinicaltrials |
| NCT07284758 | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(MOMENTUM) | recruiting | Phase 2 | 100 | C4 Therapeutics, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | recruiting | Phase 1 / Phase 2 | 36 | Vector Vitale LLCINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06669247 | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma(COSTIMM) | recruiting | Phase 1 / Phase 2 | 186 | Regeneron PharmaceuticalsINDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07638683 | A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). | recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06965114 | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | recruiting | Phase 1 / Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07069699 | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene | recruiting | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05442515 | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06967610 | Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07197307 | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)(CLEAR) | recruiting | Phase 2 | 120 | Universität MünsterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 92 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | recruiting | Phase 2 | 58 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07099391 | A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07272499 | Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease | recruiting | Phase 2 | 25 | Ruijin HospitalOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07335887 | Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis | recruiting | Phase 2 | 39 | Peking University People's HospitalOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07654426 | The CARDIOPROTECT Trial | recruiting | Phase 2 | 60 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 25, 2026source: clinicaltrials